Previous 10 |
Mallinckrodt reports BLA submission for StrataGraft, fuels merger speculation Mallinckrodt ( MNK ) stock moved up as the market responded to merger rumors for the company. While the name of the likely acquirer is kept under covers, the rumors have helped the company stock, which has seen...
Calliditas Therapeutics (NASDAQ: CALT ) : Q2 GAAP EPS of -SEK1.50. More news on: Calliditas Therapeutics AB (publ), Earnings news and commentary, Stocks on the move, Read more ...
Calliditas Therapeutics ( CALT -0.3% ) has agreed to acquire a 62.7% interest in Genkyotex through an off-market block trade of 7.2M Genkyotex, for €20.3M at €2.80/share. More news on: Calliditas Therapeutics AB (publ), Merger & acquisition news, Health...
Successful capital raise on NASDAQ STOCKHOLM , Aug. 13, 2020 /PRNewswire/ -- "In June we successfully closed a $90m U.S. IPO on NASDAQ, which including the greenshoe that was exercised in July, resulted in gross proceeds of $97m in total. This successful and pioneering trans...
STOCKHOLM , Aug. 13, 2020 /PRNewswire/ -- Transaction adds late-stage orphan pipeline asset and platform in inflammation and fibrosis. Calliditas to acquire 62.7% of Genkyotex for €20.3M in cash at €2.80 per share in an off-market transaction. Following the closing of the c...
STOCKHOLM , Aug. 11, 2020 /PRNewswire/ -- On August 13, 2020 , at 07:00 am CET , Calliditas Therapeutics ("Calliditas") will publish its business update for the second quarter 2020. Calliditas will also host a telephone conference, which will include a presentation of the results, on th...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...
2024-06-30 09:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Calliditas provides setanaxib patent update PR Newswire STOCKHOLM , June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) h...